Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: Absence of antigenemia following challenge

Antiviral Research

Volumn 89, Issue 1, 2011, Pages 119-123

  Langhammer, Stefan ^a   Hübner, Janine ^b   Jarrett, Oswald ^c   Kurth, Reinhard ^a   Denner, Joachim ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b LABOKLIN GMBH AND CO KG   (Germany)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antiretroviral vaccine; Neutralizing antibodies

Indexed keywords

FELINE LEUKEMIA VIRUS A P15E VACCINE; FELINE LEUKEMIA VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; MONTANIDE ISA 720; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN DETECTION; ARTICLE; CAT; CONTROLLED STUDY; EPITOPE MAPPING; FELINE LEUKEMIA VIRUS; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAT DISEASES; CATS; IMMUNIZATION, SECONDARY; LEUKEMIA VIRUS, FELINE; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS; VACCINATION; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES; VIREMIA;

FELINE LEUKEMIA VIRUS;

EID: 78650893879     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.011     Document Type: Article

References (22)

1. Denner J. Immunosuppression by retroviruses: implications for xenotransplantation. Ann. N.Y. Acad. Sci. 1998, 862:75-86.
2. Denner J. Endogenous retroviruses. Retroviruses: Molecular Biology, Genomics and Pathogenesis 2010, 35-69. Caister Academic Press, Hethersett, Norwich. R. Kurth, N. Bannert (Eds.).
3. Fiebig U., Eschricht M., Schmolke M., Kurth R., Denner J. Mode of interaction between the HIV-1 neutralizing monoclonal antibody 2F5 and its epitope. AIDS 2009, 23:887-895.
4. Fiebig U., Hartmann M.G., Bannert N., Kurth R., Denner J. Transspecies transmission of the endogenous koala retrovirus (KoRV). J. Virol. 2006, 80:5651-5654.
5. Fiebig U., Stephan O., Kurth R., Denner J. Neutralising antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation?. Virology 2003, 307:406-413.
6. Flynn J.N., Hanlon L., Jarrett O. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology 2000, 101:120-125.
7. Harbour D.A., Gunn-Moore D.A., Gruffydd-Jones T.J., Caney S.M., Bradshaw J., Jarrett O., Wiseman A. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine. Vaccine 2002, 20:2866-2872.
8. Ho J., Uger R.A., Zwick M.B., Luscher M.A., Barber B.H., MacDonald K.S. Conformational constraints imposed on a pan-neutralising HIV-1 antibody epitope result in increased antigenicity but not neutralising response. Vaccine 2005, 23:1559-1573.
9. Hofmann-Lehmann R., Cattori V., Tandon R., Boretti F.S., Meli M.L., Riond B., Lutz H. How molecular methods change our views of FeLV infection and vaccination. Vet. Immunol. Immunopathol. 2008, 123:119-123.
10. Hofmann-Lehmann R., Tandon R., Boretti F.S., Meli M.L., Willi B., Cattori V., Gomes-Keller M.A., Ossent P., Golder M.C., Flynn J.N., Lutz H. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 2005, 24:1087-1094.
11. Hoover E.A., Schaller J.P., Mathes L.E., Olsen R.G. Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated. Infect. Immun. 1977, 16:54-59.
12. Jarrett O., Russell P.H., Stewart M.F. Protection of kittens from feline leukaemia virus infection by maternally-derived antibody. Vet. Rec. 1977, 101:304-305.
13. Joyce J.G., Hurni W.M., Bogusky M.J., Garsky V.M., Liang X., Citron M.P., Danzeisen R.C., Miller M.D., Shiver J.W., Keller P.M. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralising responses in vitro. Implications for vaccine design. J. Biol. Chem. 2002, 277:45811-45820. Erratum in: J. Biol. Chem. 2003 278, 5492.
14. Langhammer S., Fiebig U., Kurth R., Denner J. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 2005, 23:3341-3348.
15. Langhammer S., Fiebig U., Kurth R., Denner J. Increased neutralizing antibody response after simultaneous immunization with leucogen and the feline leukemia virus transmembrane protein. Intervirology 2010, 54:78-86.
16. Langhammer S., Hübner J., Kurth R., Denner J. Antibodies neutralising feline leukemia virus (FeLV) in cats immunised with the transmembrane envelope protein p15E. Immunology 2006, 117:229-237.
17. Lu Y., Xiao Y., Ding J., Dierich M.P., Chen Y.H. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralising epitopes on human immunodeficiency virus-1 envelope protein. Scand. J. Immunol. 2000, 51:497-501.
18. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralising epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
19. Ruprecht R.M., Ferrantelli F., Kitabwalla M., Xu W., McClure H.M. Antibody protection: passive immunisation of neonates against oral AIDS virus challenge. Vaccine 2003, 21:3370-3373.
20. Schlecht-Louf G., Renard M., Mangeney M., Letzelter C., Richaud A., Ducos B., Bouallaga I., Heidmann T. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3782-3787.
21. Weiss C.D. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev. 2003, 5:214-221.
22. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralising antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.